A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer

Autor: Hernando-Calvo, Alberto, Han, Ming, Ayodele, Olubukola, Wang, Ben X., Bruce, Jeffrey P., Abbas-Aghababazadeh, Farnoosh, Vila-Casadesús, Maria, Sanz-Garcia, Enrique, Yang, S.Y. Cindy, Berman, Hal K., Vivancos, Ana, Lam, Bernard, Lungu, Ilinca, Salawu, Abdulazeez, Stayner, Lee-Anne, Haibe-Kains, Benjamin, Bedard, Philippe L., Avery, Lisa, Razak, Albiruni R.A., Pugh, Trevor J., Spreafico, Anna, Siu, Lillian L., Hansen, Aaron R.
Zdroj: In Clinical Colorectal Cancer September 2024 23(3):272-284
Databáze: ScienceDirect
Externí odkaz: